Stay updated on Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial page
- ChecktodayChange DetectedThe revision tag on the page updated from v3.6.4 to v3.6.5, replacing the previous version in the revision history to indicate a small update to the page’s version tag.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4. This indicates a new release of the page without changes to study content.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page revision tag was updated from v3.6.2 to v3.6.3. This indicates an updated build/version of the ClinicalTrials.gov page without changes to its content or data.SummaryDifference0.1%

- Check43 days agoChange DetectedPlatform revision updated from v3.6.0 to v3.6.2, indicating an updated build of the site. This change does not modify study data or visible content on the page.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page now marks recruitment as closed ('No longer looking for participants') and adds user guidance sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study'), while updating the revision label to v3.6.0 and standardizing the Intervention/Treatment heading (replacing Intervention / Treatment with Intervention/Treatment).SummaryDifference0.4%

- Check65 days agoChange DetectedRevision: v3.5.5 is now displayed, replacing Revision: v3.5.4. This indicates a minor site version update to the platform's metadata with no changes to study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial page.